GB1357737A - Sustained release pharmaceutical compositions - Google Patents

Sustained release pharmaceutical compositions

Info

Publication number
GB1357737A
GB1357737A GB4816770A GB4816770A GB1357737A GB 1357737 A GB1357737 A GB 1357737A GB 4816770 A GB4816770 A GB 4816770A GB 4816770 A GB4816770 A GB 4816770A GB 1357737 A GB1357737 A GB 1357737A
Authority
GB
United Kingdom
Prior art keywords
asa
polysiloxane
cellulose
toluene
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4816770A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARPIC SA
Original Assignee
ARPIC SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ARPIC SA filed Critical ARPIC SA
Priority to GB4816770A priority Critical patent/GB1357737A/en
Priority to US00184634A priority patent/US3853988A/en
Priority to CA123,851A priority patent/CA974883A/en
Priority to ES395533A priority patent/ES395533A1/en
Priority to FR7135618A priority patent/FR2110314B1/fr
Priority to DE19712149699 priority patent/DE2149699A1/en
Priority to DK487571AA priority patent/DK129434B/en
Priority to SE7112796A priority patent/SE382560B/en
Publication of GB1357737A publication Critical patent/GB1357737A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1357737 Sustained release compositions ETABS ARPIC SA 23 Sept 1971 [9 Oct 1970] 48167/70 Heading A5B Sustained release pharmaceutical compositions comprising a matrix formed from acetyl salicylic acid (ASA) or a pharmaceutically acceptable salt (e.g. Na or Ca salts) or complex thereof (e.g. complexes with glycine or urea), or physiologically acceptable polysiloxane and a water-insoluble cellulose ether or ester may be prepared by combining ASA (or the salt or complex thereof), a polysiloxane and a waterinsoluble cellulose ether or ester in a liquid medium and removing the liquid medium. The polysiloxane may be a dialkyl polysiloxane such as dimethylpolysiloxane and the cellulose derivative is preferably ethyl cellulose or cellulose acetobutyrate. The compositions may be in the form of dosage units, such as capsules, tablets, coated tablets, dragees, sachets, powders or granules, which may also contain a further amount of ASA in addition to the ASA incorporated in the matrix. The liquid medium may comprise an aliphatic halohydrocarbon such as methylene chloride, chloroform or carbon tetrachloride and/or an aromatic hydrocarbon such as benzene or toluene. A solution of the polysiloxane in toluene may be admixed with a solution of the cellulose ether or ester in toluene and methylene chloride in the presence of ASA in solid form.
GB4816770A 1970-10-09 1970-10-09 Sustained release pharmaceutical compositions Expired GB1357737A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GB4816770A GB1357737A (en) 1970-10-09 1970-10-09 Sustained release pharmaceutical compositions
US00184634A US3853988A (en) 1970-10-09 1971-09-28 Sustained released pharmaceutical compositions
CA123,851A CA974883A (en) 1970-10-09 1971-09-28 Acetylsalicylic acid sustained release preparations
ES395533A ES395533A1 (en) 1970-10-09 1971-09-29 Sustained released pharmaceutical compositions
FR7135618A FR2110314B1 (en) 1970-10-09 1971-10-04
DE19712149699 DE2149699A1 (en) 1970-10-09 1971-10-05 Delayed release pharmaceutical compositions
DK487571AA DK129434B (en) 1970-10-09 1971-10-07 Process for the preparation of a pharmaceutical composition of acetylsalicylic acid as active substance as well as polysiloxane and a cellulose ether or ester and with gradual release of the active substance.
SE7112796A SE382560B (en) 1970-10-09 1971-10-08 PROCEDURE FOR THE PREPARATION OF ACETYL SALICYLIC ACID INCLUDING PHARMACEUTICAL ACCEPTABLE SALTS AND COMPLEX THEREOF CONTAINING DELAYED PHARMACEUTICAL COMPOSITIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4816770A GB1357737A (en) 1970-10-09 1970-10-09 Sustained release pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB1357737A true GB1357737A (en) 1974-06-26

Family

ID=10447626

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4816770A Expired GB1357737A (en) 1970-10-09 1970-10-09 Sustained release pharmaceutical compositions

Country Status (8)

Country Link
US (1) US3853988A (en)
CA (1) CA974883A (en)
DE (1) DE2149699A1 (en)
DK (1) DK129434B (en)
ES (1) ES395533A1 (en)
FR (1) FR2110314B1 (en)
GB (1) GB1357737A (en)
SE (1) SE382560B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51123814A (en) * 1975-04-22 1976-10-28 Shin Etsu Chem Co Ltd A process for preparing gradually releasable solid medicines
DE2902414A1 (en) * 1979-01-23 1980-08-07 Hoechst Ag DEPOT BODY BASED ON SILICONE RUBBER AND METHOD FOR THE PRODUCTION THEREOF
FR2514261B1 (en) * 1981-10-08 1986-08-22 Aec Chim Organ Biolog NOVEL COMPOSITION FOR COATING FOODS AND DRUGS AND GRANULES THUS COATED
DE3508097A1 (en) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt COMBINATION PRODUCT MADE OF XANTHINE DERIVATIVES AND O-ACETYLSALICYL ACID OR THEIR PHARMACOLOGICALLY COMPATIBLE SALTS AND THE USE THEREOF
FR2653338B1 (en) * 1989-10-23 1994-06-10 Dow Corning Sa FORMULATION FOR SUSTAINED RELEASE DRUGS AND THE USE THEREOF.
CA2185883C (en) * 1994-03-18 2005-08-23 Alfred Schmidt The use of dimeticone as a transport and carrier system and/or drug delivery system
DE4409357C2 (en) * 1994-03-18 1996-10-17 Upmeyer Hans Juergen Use of Dimeticon to eradicate Heliobacter pylori
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
AU6403196A (en) * 1995-06-30 1997-02-05 Baylor University Polyester/carboxylic acid composite materials
US20110039807A1 (en) * 2009-08-13 2011-02-17 Kim Hyoung-Chun Anti-parkinsonian compound acetylsalicylic acid maltol ester
CN104603194B (en) 2012-07-17 2017-11-24 陶氏环球技术有限责任公司 Composition comprising organic liquid diluent and low-viscosity cellulose ether

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
GB971486A (en) * 1960-04-01 1964-09-30 Rech S Pharma Et Scient Therapeutic compositions comprising aspirin and polysiloxanes
US3133863A (en) * 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
AU407324B2 (en) * 1962-05-01 1970-10-28 Smith, Kline & French Laboratories Powdered silicone products and processes
IL26885A (en) * 1965-12-06 1970-10-30 Smith Kline French Lab Pharmaceutical silicone compositions
US3518344A (en) * 1967-10-02 1970-06-30 Miles Lab Tableting lubricant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations

Also Published As

Publication number Publication date
DE2149699A1 (en) 1972-04-13
FR2110314B1 (en) 1975-06-06
DK129434B (en) 1974-10-14
DK129434C (en) 1975-03-10
ES395533A1 (en) 1974-10-16
US3853988A (en) 1974-12-10
FR2110314A1 (en) 1972-06-02
SE382560B (en) 1976-02-09
CA974883A (en) 1975-09-23

Similar Documents

Publication Publication Date Title
GB1357737A (en) Sustained release pharmaceutical compositions
AR065827A2 (en) DOSAGE FORMS OF SERTRALINE SUSTAINED RELEASE, SERTRALINE SALTS, PHARMACEUTICAL COMPOSITION, PROCEDURE AND PREPARATION AND ITS USE IN THERAPY
KR880004806A (en) Spray drying acetaminophen
ES2064564T3 (en) PULSE PRESSURE RELEASE SYSTEM OF DAILY UNIT DOSE OF MINOCYCLINE.
GB1298494A (en) Phenylethanolamine derivatives
US3966923A (en) Medicaments intended for the prevention and treatment of ischemic disturbances
US3144387A (en) Anti-inflammatory compositions
GB1015787A (en) Tris-(p-methoxyphenyl)ethylene derivatives
JP2974370B2 (en) Sialidase inhibitors
IL102949A0 (en) Substituted mandelic acid derivatives,their preparation and pharmaceutical compositions containing them
US4975423A (en) Inhibition of tumor development
EP0302421A2 (en) Alpha-carotene for inhibiting the growth of cancer cells
GB1276089A (en) Pharmaceutical preparations
ES247237A1 (en) Coated pharmaceutical granules and tablets thereof
US3362879A (en) Tyrosine tranquilizing compositions and methods of treatment
US3155577A (en) Tasteless dioctylsulfosuccinate composition and method of making same
US3242049A (en) Process for making enterically useful complex of spiramycin and product thereof
FI84697B (en) A PROCEDURE FOR THE FRAMSTATION OF A PHARMACOLOGICAL COMPOSITION WITH DERIVATIVES OF PEROXIDE DOSPHOSPHORUS.
GB1460325A (en) Pharmaceutical composition intended for relieving pain and producing analgesia
GB791644A (en) Barbiturate pharmaceutical preparations
IE35419L (en) Pharmaceutical composition containing cyclobenzaprine
IE34590L (en) Phenylethanolamine derivatives
GB1435923A (en) Pharmaceutical compositions for treating vascular diseases
NL8003299A (en) AGENT FOR COMBATING THE GROWTH OF CANCER CELLS AND METHOD FOR PREPARING THESE.
US2726984A (en) Composition for combatting amoebiasis comprising 1:2-bis(4'-arsono-phenylamino)-ethane

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PLNP Patent lapsed through nonpayment of renewal fees